High grade neuroendocrine lung tumors: Pathological characteristics, surgical management and prognostic implications

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 404-409

  Grand, Bertrand ^a   Cazes, Aurélie ^a   Mordant, Pierre ^a   Foucault, Christophe ^a   Dujon, Antoine ^b   Guillevin, Elizabeth Fabre ^a   Barthes, Françoise Le Pimpec ^a   Riquet, Marc ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Cedar Surgical Centre   (France)

Author keywords

Large cell lung cancer; Lung cancer; Multimodality treatments; Neuroendocrine lung cancer; Surgery

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SMOKING HABIT; SURVIVAL; SURVIVAL RATE; THORACOTOMY; TUMOR VOLUME;

LARGE CELL LUNG CANCER; LUNG CANCER; MULTIMODALITY TREATMENTS; NEUROENDOCRINE LUNG CANCER; SURGERY;

AGED; CARCINOMA, LARGE CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; TUMOR BURDEN;

EID: 84881667078     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.008     Document Type: Article

References (29)

1. Brambilla E., Pugatch B., Geisinger K. Large cell carcinoma. WHO histological classification of tumours. Histological typing of lung and pleural tumours 1999, 45-50. Springer-Verlag, Berlin. 3rd ed. W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, E. Brambilla (Eds.).
2. Travis W.D., Linnoila R.I., Tsokos M.G., Hitchcock C.L., Cutler G.B., Nieman L., et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15:529-553.
3. Iyoda A., Hiroshima K., Moriya Y., Sekine Y., Shibuya K., Iizasa T., et al. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg 2006, 132:312-315.
4. American Joint Committee on Cancer (AJCC) cancer staging handbook. From the AJCC cancer staging manual 2010, 299-323. Springer, Chicago. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
5. Kwiatkowski F., Girard M., Hacene K., Berlie J. SEM (Statistiques, Epidemiologie, Médicine): un outil de gestion informatique et statistique adapté à la recherche en cancerologie. Bull Cancer 2000, 87(10):715-721.
6. Hammond M.E., Sause W.T. Large cell neuroendocrine tumors of the lung. Clinical significance and histopathologic definition. Cancer 1985, 56:1624-1629.
7. Warren W.H., Gould V.E., Faber L.P., Kittle C.F., Memoli V.A. Neuroendocrine neoplasms of the bronchopulmonary tract. Classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 1985, 89:819-825.
8. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hemerlink, C.C. Harris (Eds.).
9. Takei H., Asamura H., Maeshima A., Suzuki K., Kondo H., Niki T., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002, 124:285-292.
10. Hage R., Seldenrijk K., de Bruin P., van Swieten H., van den Bosch J. Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardio-Thorac Surg 2003, 23:457-460.
11. Zacharias J., Nicholson A.G., Ladas G.P., Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 2003, 75:348-352.
12. Doddoli C., Barlesi F., Chetaille B., Garbe L., Thomas P., Giudicelli R., et al. Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg 2004, 77:1168-1172.
13. Paci M., Cavazza A., Annessi V., Putrino I., Ferrari G., De Franco S., et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004, 77:1163-1167.
14. Veronesi G., Morandi U., Alloisio M., Terzi A., Cardillo G., Filosso P., et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006, 53:111-115.
15. Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006, 24:70-76.
16. Fournel L., Falcoz P.E., Alifano M., Charpentier M.C., Boudaya M.S., Magdeleinat P., et al. Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience. Eur J Cardio-Thorac Surg 2013, 43:111-114.
17. Battafarano R.J., Fernandez F.G., Ritter J., Meyers B.F., Guthrie T.J., Cooper J.D., et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005, 130:166-172.
18. Graziano S.L., Tatum A., Herndon J.E., Box J., Memoli V., Green M.R., et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 2001, 33:115-123.
19. Dresler C.M., Ritter J.H., Patterson G.A., Ross E., Bailey M.S., Wick M.R. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997, 63:180-185.
20. Iyoda A., Hiroshima K., Toyozaki T., Haga Y., Baba M., Fujisawa T., et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer 2001, 92:1108-1112.
21. Rossi G., Cavazza A., Marchioni A., Longo L., Migaldi M., Sartori G., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23:8774-8785.
22. Iyoda A., Hiroshima K., Moriya Y., Takiguchi Y., Sekine Y., Shibuya K., et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006, 82:1802-1807.
23. Sarkaria I.S., Iyoda A., Roh M.S., Sica G., Kuk D., Sima C.S., et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg 2011, 92:1180-1186.
24. Filosso P.L., Ruffini E., Oliaro A., Rena O., Casadio C., Mancuso M., et al. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg 2005, 129:819-824.
25. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
26. Zakowski M.F., Ladanyi M., Kris M.G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006, 355:213-215.
27. Tatematsu A., Shimizu J., Murakami Y., Horio Y., Nakamura S., Hida T., et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14:6092-6096.
28. De Pas T.M., Giovannini M., Manzotti M., Trifirò G., Toffalorio F., Catania C., et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol 2011, 29:e819-e822.
29. Sturm N., Rossi G., Lantuejoul S., Papotti M., Frachon S., Claraz C., et al. Expression of thyroid transcription factor 1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002, 33(2):175-182.